The acquisition of Bausch + Lomb by Valeant Pharmaceuticals International is now completed. As reported previously by Eyewear Intelligence, the Canadian company will pay $4.5 billion in cash to the current owners, an investor group headed by the private equity firm Warburg Pincus, and another $4.2 billion in cash to ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.